The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab

JAMA Intern Med. 2020 Feb 1;180(2):315-317. doi: 10.1001/jamainternmed.2019.4694.

Authors

Myung S Kim¹, Vinay Prasad^{1

2

3}

Affiliations

¹ Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland.
² Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland.
³ Center for Health Care Ethics, Oregon Health and Science University, Portland.

Abstract

This study reviews publications and the level of evidence for US Food and Drug Administration–approved and off-label indications for eculizumab.

Publication types

Review

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Atypical Hemolytic Uremic Syndrome / drug therapy*
Autoimmune Diseases / drug therapy*
Clinical Trials as Topic
Complement Inactivating Agents / therapeutic use*
Evidence-Based Medicine
Graft Rejection / drug therapy
Graft Rejection / prevention & control
Hematologic Diseases / drug therapy*
Hemoglobinuria, Paroxysmal / drug therapy*
Humans
Kidney Diseases / drug therapy*
Kidney Transplantation
Myasthenia Gravis / drug therapy*
Observational Studies as Topic
Off-Label Use
Reperfusion Injury / prevention & control
Single-Case Studies as Topic

Substances

Antibodies, Monoclonal, Humanized
Complement Inactivating Agents
eculizumab